Demographic and clinical characteristics of the 2-institution cohort
| Characteristic . | Value . |
|---|---|
| All patients, n | 32 |
| Male | 14 (43.7) |
| Female | 18 (56.3) |
| Age, range | 53-87 |
| Mean ± SD | 74.1 ± 9.1 |
| Median (IQR) | 77 (65.8-80.3) |
| >80 y | 9 (28.1) |
| >85 y | 4 (12.5) |
| Comorbidity and underlying conditions | |
| Comorbidity index, mean ± SD | 1.6 ± 1.4 |
| ECOG performance status score, mean ± SD | 2.1 ± 0.9 |
| 4 | 3 |
| 3 | 6 |
| 2 | 13 |
| 1 | 10 |
| Underlying illnesses∗ | |
| None (idiopathic) | 19 (59.4) |
| Autoimmune | 8 (25) |
| Bullous pemphigoid | 2 |
| Graves hyperthyroidism | 2 |
| Hashimoto hypothyroidism | 2 |
| Rheumatoid arthritis | 2 |
| Systemic lupus erythematosus | 1 |
| Neoplastic | 7 (21.9) |
| Common comorbid conditions∗ | |
| Hypertension | 18 (56.3) |
| Cardiovascular disease | 10 (31.3) |
| Type 2 diabetes mellitus | 6 (18.8) |
| Chronic obstructive pulmonary disease | 6 (18.8) |
| AHA initial severity | |
| Initial FVIII, mean ± SD, IU/dL | 3 ± 4.4 |
| Median (IQR) | 1 (0-4.3) |
| Initial inhibitor, mean ± SD, BU | 177.9 ± 552.2 |
| Median (IQR) | 17 (5.7-112.5) |
| >20 BU | 14 (43.8) |
| >100 BU | 10 (31.3) |
| >1000 BU | 1 (3.1) |
| No. of CyDRi cycles needed for CR | |
| All patients, mean ± SD | 1.66 ± 1.52 |
| All patients, median (IQR) | 1 (1-2) |
| 1 cycle only | 22 |
| 2 cycles | 5 |
| 3 cycles | 4 |
| 9 cycles | 1 |
| Characteristic . | Value . |
|---|---|
| All patients, n | 32 |
| Male | 14 (43.7) |
| Female | 18 (56.3) |
| Age, range | 53-87 |
| Mean ± SD | 74.1 ± 9.1 |
| Median (IQR) | 77 (65.8-80.3) |
| >80 y | 9 (28.1) |
| >85 y | 4 (12.5) |
| Comorbidity and underlying conditions | |
| Comorbidity index, mean ± SD | 1.6 ± 1.4 |
| ECOG performance status score, mean ± SD | 2.1 ± 0.9 |
| 4 | 3 |
| 3 | 6 |
| 2 | 13 |
| 1 | 10 |
| Underlying illnesses∗ | |
| None (idiopathic) | 19 (59.4) |
| Autoimmune | 8 (25) |
| Bullous pemphigoid | 2 |
| Graves hyperthyroidism | 2 |
| Hashimoto hypothyroidism | 2 |
| Rheumatoid arthritis | 2 |
| Systemic lupus erythematosus | 1 |
| Neoplastic | 7 (21.9) |
| Common comorbid conditions∗ | |
| Hypertension | 18 (56.3) |
| Cardiovascular disease | 10 (31.3) |
| Type 2 diabetes mellitus | 6 (18.8) |
| Chronic obstructive pulmonary disease | 6 (18.8) |
| AHA initial severity | |
| Initial FVIII, mean ± SD, IU/dL | 3 ± 4.4 |
| Median (IQR) | 1 (0-4.3) |
| Initial inhibitor, mean ± SD, BU | 177.9 ± 552.2 |
| Median (IQR) | 17 (5.7-112.5) |
| >20 BU | 14 (43.8) |
| >100 BU | 10 (31.3) |
| >1000 BU | 1 (3.1) |
| No. of CyDRi cycles needed for CR | |
| All patients, mean ± SD | 1.66 ± 1.52 |
| All patients, median (IQR) | 1 (1-2) |
| 1 cycle only | 22 |
| 2 cycles | 5 |
| 3 cycles | 4 |
| 9 cycles | 1 |
Data are expressed as n (%) unless otherwise indicated.
Numbers are not additive because overlaps occurred (eg, patient 3B#4 had RA and pemphigoid). Details are provided in supplemental Table 1.